Managing Director / CEO
Wolfgang Kintzel is a biologist by training (MSc, Diplom Biologe). Wolfgang joined Schering/Berlex gaining quickly more responsibility in various sales and marketing functions. With now more than 16 years of experience in different roles within the pharmaceutical, medical device and biotech industry in leading European and US based organizations he had full P&L responsibility up to 100 Mio €. Wolfgang managed organizations up to 170 employees. From 2000 - 2008 he built up amaxa AG as global VP Marketing & Sales from a true start-up situation to a fully integrated company complemented with an outstanding M&A experience in 2008 when the company was sold to Lonza Group Ltd., Switzerland.
Dr. Rainer Lichtenberger
Managing Director / CFO/COO
Rainer Lichtenberger has more than 20 years of management experience in renowned companies. Being Pharmacist by training, he joined Merck KGaA in 1988 after finishing his Ph.D. thesis in Pharmaceutical Technology. With Merck KGaA, he held various positions of increasing responsibility in R&D, project management and global marketing, among them head business unit „Osteoporosis & Womens Health" and vice president of global marketing. In 2002, Dr. Lichtenberger joined the Merckle/Ratiopharm group on executive board level, in his role as corporate vice president business development and international marketing. Since 2004 he established a private venture-financed German biopharmaceutical development company, Neuraxo Biopharmaceuticals GmbH, out of an university spin-off and managed a major series A venture round with 12 Mio € volume in 2005.
Dr. Nicole Faust
Senior Vice President Development and Services
Nicole Faust received her Ph.D. in Molecular and Cell Biology from the University of Freiburg in 1995. After a post-doctoral period at the EMBL, Heidelberg, she joined Artemis-Pharmaceuticals GmbH, Cologne in 1999 as a Research Scientist. In 2001 she took over responsibility for the Molecular Technology group as Associate Director R&D. In 2004 she started a position with amaxa GmbH, now Lonza Cologne GmbH. As Director R&D she was responsible for developing transfection technologies, for the cell-based assay program, and for establishing and running the cell line development services. She joined CEVEC in May 2011.
Dr. Hartmut Tintrup
Vice President Business Development & Licensing
Hartmut Tintrup received his Ph.D. in 1998 from Frankfurt University, Germany. After finishing his Ph.D. thesis at the Max-Planck-Institute for Brain Research in Frankfurt he worked first as a Research Scientist at Artemis Pharmaceuticals GmbH, Cologne and then at Exelixis Inc., South San Francisco, USA. In 2004, Hartmut joined the US subsidiary of amaxa AG (now Lonza Cologne AG) to support US and global sales in various positions including industrial sales, export and tactical marketing. He joined CEVEC in 2010.